Reliable Genotypic Tropism Tests for the Major HIV-1 Subtypes

Over the past decade antiretroviral drugs have dramatically improved the prognosis for HIV-1 infected individuals, yet achieving better access to vulnerable populations remains a challenge. The principal obstacle to the CCR5-antagonist, maraviroc, from being more widely used in anti-HIV-1 therapy regimens is that the pre-treatment genotypic “tropism tests” to determine virus susceptibility to maraviroc have been developed primarily for HIV-1 subtype B strains, which account for only 10% of infections worldwide. We therefore developed PhenoSeq, a suite of HIV-1 genotypic tropism assays that are highly sensitive and specific for establishing the tropism of HIV-1 subtypes A, B, C, D and circulating recombinant forms of subtypes AE and AG, which together account for 95% of HIV-1 infections worldwide. The PhenoSeq platform will inform the appropriate use of maraviroc and future CCR5 blocking drugs in regions of the world where non-B HIV-1 predominates, which are burdened the most by the HIV-1 pandemic.

[1]  Anders Karlsson,et al.  Maraviroc for previously treated patients with R5 HIV-1 infection. , 2008, The New England journal of medicine.

[2]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[3]  Jacques Corbeil,et al.  A new perspective on V3 phenotype prediction. , 2003, AIDS research and human retroviruses.

[4]  Thomas Lengauer,et al.  Bioinformatics prediction of HIV coreceptor usage , 2007, Nature Biotechnology.

[5]  H. Ullum,et al.  Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection , 2013, PloS one.

[6]  J. Margolick,et al.  Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.

[7]  Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection , 2013, Retrovirology.

[8]  H. Schuitemaker,et al.  Clinical significance of HIV-1 coreceptor usage , 2011, Journal of Translational Medicine.

[9]  G. Raghava,et al.  Hybrid Approach for Predicting Coreceptor Used by HIV-1 from Its V3 Loop Amino Acid Sequence , 2013, PloS one.

[10]  Wei Huang,et al.  Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations , 2007, Journal of Virology.

[11]  R. Doms,et al.  V3 Loop Truncations in HIV-1 Envelope Impart Resistance to Coreceptor Inhibitors and Enhanced Sensitivity to Neutralizing Antibodies , 2007, PLoS pathogens.

[12]  Alexander Thielen,et al.  Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. , 2011, The Journal of infectious diseases.

[13]  D. Struck,et al.  HIV-1 Tropism Determination Using a Phenotypic Env Recombinant Viral Assay Highlights Overestimation of CXCR4-Usage by Genotypic Prediction Algorithms for CRRF01_AE and CRF02_AG , 2013, PloS one.

[14]  C. Neff,et al.  Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse Model , 2010, PloS one.

[15]  H. Moriyama,et al.  Molecular determinants of HIV-1 subtype C coreceptor transition from R5 to R5X4. , 2010, Virology.

[16]  John R Mascola,et al.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. , 2007, Virology.

[17]  B. Cullen,et al.  Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. , 1991, Science.

[18]  C. Charpentier,et al.  Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study , 2010, Antimicrobial Agents and Chemotherapy.

[19]  Noah G. Hoffman,et al.  Variability in the Human Immunodeficiency Virus Type 1 gp120 Env Protein Linked to Phenotype-Associated Changes in the V3 Loop , 2002, Journal of Virology.

[20]  P. Harrigan,et al.  Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies , 2010, AIDS.

[21]  Mark L. Pearson,et al.  Complete nucleotide sequence of the AIDS virus, HTLV-III , 1985, Nature.

[22]  François Laviolette,et al.  HIV-1 coreceptor usage prediction without multiple alignments: an application of string kernels , 2008, Retrovirology.

[23]  D. Cooper,et al.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. , 2010, The Journal of infectious diseases.

[24]  P. Harrigan,et al.  Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes. , 2013, AIDS research and human retroviruses.

[25]  R. Wood,et al.  The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa , 2012, Journal of the International AIDS Society.

[26]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[27]  Bernard Hirschel,et al.  Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. , 2008, The New England journal of medicine.

[28]  N. Ghosh,et al.  Genetic analysis of HIV-1 Circulating Recombinant Form 02_AG, B and C subtype-specific envelope sequences from Northern India and their predicted co-receptor usage , 2009, AIDS research and therapy.

[29]  W. Paxton,et al.  Intrapatient Alterations in the Human Immunodeficiency Virus Type 1 gp120 V1V2 and V3 Regions Differentially Modulate Coreceptor Usage, Virus Inhibition by CC/CXC Chemokines, Soluble CD4, and the b12 and 2G12 Monoclonal Antibodies , 2004, Journal of Virology.

[30]  B. Clotet,et al.  A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. , 2009, The Journal of infectious diseases.

[31]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[32]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[33]  R. Swanstrom,et al.  Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. , 2001, Virology.

[34]  P. Massip,et al.  Genotypic Prediction of HIV-1 CRF01-AE Tropism , 2012, Journal of Clinical Microbiology.

[35]  R. Kagan,et al.  A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients , 2012, PloS one.

[36]  P. Massip,et al.  Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[37]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.

[38]  A. Capovilla,et al.  Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. , 2008, AIDS research and human retroviruses.

[39]  Paul A. Ramsland,et al.  Alternative Coreceptor Requirements for Efficient CCR5- and CXCR4-Mediated HIV-1 Entry into Macrophages , 2011, Journal of Virology.

[40]  T. Wrin,et al.  Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5 , 2008 .

[41]  M. Negishi,et al.  Differential prevalence of HIV type 1 subtype B and CRF01_AE among different sexual transmission groups in Tokyo, Japan, as revealed by subtype-specific PCR. , 2003, AIDS research and human retroviruses.

[42]  M. Jensen,et al.  Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  Sikhulile Moyo,et al.  Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. , 2012, Virology.

[44]  J. Zamora,et al.  Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected , 2011, PloS one.

[45]  Natalia Chueca,et al.  Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes , 2008, Journal of Clinical Microbiology.

[46]  A. Capovilla,et al.  Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa , 2008, AIDS.

[47]  Christos J. Petropoulos,et al.  Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism , 2006, Antimicrobial Agents and Chemotherapy.

[48]  P. Ghys,et al.  Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004 , 2006, AIDS.

[49]  M. Churchill,et al.  Differences in coreceptor specificity contribute to alternative tropism of HIV-1 subtype C for CD4+ T-cell subsets, including stem cell memory T-cells , 2014, Retrovirology.

[50]  B. Margolin,et al.  Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein. , 1997, Virology.

[51]  M. Essex,et al.  Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of human immunodeficiency virus type 1 gp120 interaction with the CCR5 coreceptor. , 2007, Virology.

[52]  Michal Sharon,et al.  Molecular switch for alternative conformations of the HIV-1 V3 region: Implications for phenotype conversion , 2006, Proceedings of the National Academy of Sciences.

[53]  O. Laeyendecker,et al.  High prevalence of CXCR4 usage among treatment-naive CRF01_AE and CRF51_01B-infected HIV-1 subjects in Singapore , 2013, BMC Infectious Diseases.

[54]  P. Ghys,et al.  Global trends in molecular epidemiology of HIV-1 during 2000–2007 , 2011, AIDS.

[55]  L. Vandekerckhove,et al.  Maraviroc: integration of a new antiretroviral drug class into clinical practice. , 2008, The Journal of antimicrobial chemotherapy.

[56]  J. Goudsmit,et al.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.

[57]  J. Anglister,et al.  Correlated mutations at gp120 positions 322 and 440: Implications for gp120 structure , 2008, Proteins.

[58]  F. Ceccherini‐Silberstein,et al.  Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120V3 signatures in the regulation of Co-Receptor usage , 2011, Retrovirology.

[59]  P. Harrigan,et al.  Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  L. Ferradini,et al.  Prediction of HIV Type 1 Subtype C Tropism by Genotypic Algorithms Built From Subtype B Viruses , 2010, Journal of acquired immune deficiency syndromes.

[61]  P. Massip,et al.  Genotypic Prediction of Human Immunodeficiency Virus Type 1 CRF02-AG Tropism , 2009, Journal of Clinical Microbiology.

[62]  F. Wiesmann,et al.  Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals. , 2007, European journal of medical research.

[63]  P. Harrigan,et al.  Population-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT Trial , 2012, Journal of acquired immune deficiency syndromes.

[64]  M. Churchill,et al.  Covariance of Charged Amino Acids at Positions 322 and 440 of HIV-1 Env Contributes to Coreceptor Specificity of Subtype B Viruses, and Can Be Used to Improve the Performance of V3 Sequence-Based Coreceptor Usage Prediction Algorithms , 2014, PloS one.

[65]  Elena Delgado,et al.  Improvement of HIV-1 coreceptor tropism prediction by employing selected nucleotide positions of the env gene in a Bayesian network classifier. , 2013, The Journal of antimicrobial chemotherapy.

[66]  M. Churchill,et al.  Viral tropism, fitness and pathogenicity of HIV-1 subtype C , 2010 .

[67]  T. Koivula,et al.  Higher mortality in HIV-2/HTLV-1 co-infected patients with pulmonary tuberculosis in Guinea-Bissau, West Africa, compared to HIV-2-positive HTLV-1-negative patients. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[68]  J. Izopet,et al.  Algorithm-Based Prediction of HIV-1 Subtype D Coreceptor Use , 2013, Journal of Clinical Microbiology.

[69]  Z. Su,et al.  Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  C. Cheng‐Mayer,et al.  Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Lynn Morris,et al.  A Reliable Phenotype Predictor for Human Immunodeficiency Virus Type 1 Subtype C Based on Envelope V3 Sequences , 2006, Journal of Virology.

[72]  F. Ceccherini‐Silberstein,et al.  Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage. , 2012, Virus research.

[73]  F. Månsson,et al.  Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease - indication of an evolving epidemic in West Africa , 2010, Retrovirology.

[74]  T. Ndung’u,et al.  Genetic Characteristics, Coreceptor Usage Potential and Evolution of Nigerian HIV-1 Subtype G and CRF02_AG Isolates , 2011, PloS one.

[75]  M. Churchill,et al.  CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm , 2013, Retrovirology.

[76]  P. Massip,et al.  Genotypic prediction of HIV-1 subtype D tropism , 2011, Retrovirology.